%0 Journal Article
%A Suarez-Carmona, Meggy
%A Halama, Niels
%T Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer.
%J Trends in cancer
%V 10
%N 12
%@ 2405-8033
%C Amsterdam
%I Elsevier
%M DKFZ-2024-02163
%P 1093-1094
%D 2024
%Z #EA:D196#LA:D196# / 2024 Dec;10(12):1093-1094 / HI-TRON / SPOTLIGHT
%X Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.
%K MSI (Other)
%K colorectal cancer (Other)
%K dMMR (Other)
%K immune checkpoint inhibition (Other)
%K neoadjuvant therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39448335
%R 10.1016/j.trecan.2024.10.006
%U https://inrepo02.dkfz.de/record/294330